Moderna and Merck's mRNA melanoma vaccine shows success in late-stage trial

Moderna and Merck have demonstrated success with a personalized mRNA vaccine that significantly reduced melanoma recurrence in a late-stage clinical trial. This breakthrough represents a major validation of mRNA technology and offers new hope for treating melanoma, the most aggressive form of skin cancer. The achievement comes at a critical time for mRNA therapeutics, which have faced skepticism following initial post-pandemic challenges.